Unicycive Therapeutics Inc. is a biotechnology company primarily focused on the development and commercialization of therapies for patients with kidney disease. The company works extensively on creating novel and transformative treatments, addressing significant unmet medical needs in nephrology. One of its leading candidates targets hyperphosphatemia, a common complication in patients with chronic kidney disease. Unicycive Therapeutics employs innovative drug discovery techniques to advance its pipeline of clinical and preclinical programs, aiming to improve patient quality of life and healthcare outcomes. The company's role in the biotechnology sector is to drive advancements in kidney therapy solutions, contributing to medical research and offering potential breakthroughs in treatments for chronic conditions. Founded with a commitment to science-driven approaches, Unicycive Therapeutics operates within a competitive and rapidly evolving market, collaborating with industry and academic partners to accelerate the development of its therapeutic solutions.